drugset / Trial / NCT05008237
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
Cisplatin plus weekly docetaxel as first-line chemotherapy in metastatic salivary gland cancer patients : a multicenter phase II study
Timeline
- Start
- 2014-05-02
- Primary completion
- 2022-05
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 35 mg/m2 | Other |